Oryzon Genomics SA
MAD:ORY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hunan Airbluer Environmental Protection Technology Co Ltd
SZSE:301259
|
CN |
Oryzon Genomics SA
Long-Term Debt
Oryzon Genomics SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oryzon Genomics SA
MAD:ORY
|
Long-Term Debt
€3.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
0%
|
|
|
Grifols SA
MAD:GRF
|
Long-Term Debt
€8.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Pharma Mar SA
MAD:PHM
|
Long-Term Debt
€36.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
See Also
What is Oryzon Genomics SA's Long-Term Debt?
Long-Term Debt
3.1m
EUR
Based on the financial report for Dec 31, 2025, Oryzon Genomics SA's Long-Term Debt amounts to 3.1m EUR.
What is Oryzon Genomics SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
0%
Over the last year, the Long-Term Debt growth was -5%. The average annual Long-Term Debt growth rates for Oryzon Genomics SA have been -24% over the past three years , -10% over the past five years .
